Back to Search
Start Over
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example.
- Source :
-
EJNMMI Research . 8/21/2021, Vol. 11 Issue 1, p1-7. 7p. - Publication Year :
- 2021
-
Abstract
- Background: 89Zirconium-immuno-positron emission tomography (89Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy. We aim to determine the relation between antibody tumor uptake and target concentration to improve future study design and interpretation. Methods: The relation between tumor uptake and target concentration was predicted by mathematical modeling of 89Zr-labeled antibody disposition in the tumor. Literature values for trastuzumab kinetics were used to provide an example. Results: 89Zr-trastuzumab uptake initially increases with increasing target concentration, until it levels off to a constant value. This is determined by the total administered mass dose of trastuzumab. For a commonly used imaging dose of 50 mg 89Zr-trastuzumab, uptake can discriminate between immunohistochemistry score (IHC) 0 versus 1–2–3. Conclusion: The example for 89Zr-trastuzumab illustrates the potential to assess target expression. The pitfall of false-positive findings depends on the cut-off to define clinical target positivity (i.e., IHC 3) and the administered mass dose. [ABSTRACT FROM AUTHOR]
- Subjects :
- *TRASTUZUMAB
*MONOCLONAL antibodies
Subjects
Details
- Language :
- English
- ISSN :
- 2191219X
- Volume :
- 11
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- EJNMMI Research
- Publication Type :
- Academic Journal
- Accession number :
- 152026938
- Full Text :
- https://doi.org/10.1186/s13550-021-00813-7